Earlier this month, Alvotech announced that it entered into an agreement with Fuji Pharma, giving Fuji Pharma the exclusive right to commercialize its biosimilar of Stelara® (ustekinumab) in Japan. The press release states that, in exchange for developing and providing Fuji Pharma with a commercial supply of its ustekinumab biosimilar, Alvotech will receive an upfront payment of $4.6 million with rights to receive milestone payments of up to $20 million.
The post Alvotech and Fuji Pharma Partner to Commercialize Alvotech’s Ustekinumab Biosimilar appeared first on Big Molecule Watch.